title: Blockade of fast A-type and TEA-sensitive potassium channels provide an antiparkinsonian effect in a 6-OHDA animal model.
abstract: To evaluate the effect of K+ channels inhibitors in treatment of parkinson`s disease (PD).
  
  
  
  This prospective comparative study was conducted in the Qazvin University of Medical Sciences, Iran, from April 2015 to January 2016. Male rats (n=37) received intraperitoneal doses of TEA (2 and 5 mg/kg) or 4-AP (0.5 and 1 mg/kg) twice-daily, before a stereotactic injection of 6-hydroxydopamine (6-OHDA) for the following 7 days. The 6-OHDA was injected into right medial forebrain bundle (MFB) of the rat brains. Development and severity of PD were assessed using the apomorphine-induced rotational test, the elevated body swing test and rotarod tests. Concentration of malondialdehyde (MDA), a marker of oxidative stress, was measured in rat sera.
  
  
  
  Tetraethylammonium and 4-AP significantly reduced the number of apomorphine-induced rotations and improved motor learning in the rotarod test at both doses. Administration of 4-AP and TEA together was more effective than single administration of either agent. Malondialdehyde measurement showed that pretreatment with TEA could not prevent 6-OHDA-induced oxidative stress.
  
  
  
  Our results showed that pretreatment with TEA and 4-AP has a neuroprotective effect against 6-OHDA in dopaminergic neurons in the substantia nigra.
authors.affiliation: Cellular and Molecular Research Center, Qazvin University of Medical Sciences, Qazvin, Iran.
authors.forename: Hashem
authors.initials: H
authors.lastname: Haghdoost-Yazdi
authors.forename: Hossein
authors.initials: H
authors.lastname: Piri
authors.forename: Reza
authors.initials: R
authors.lastname: Najafipour
authors.forename: Ayda
authors.initials: A
authors.lastname: Faraji
authors.forename: Negin
authors.initials: N
authors.lastname: Fraidouni
authors.forename: Tahereh
authors.initials: T
authors.lastname: Dargahi
authors.forename: Mahmud
authors.initials: M
authors.lastname: Alipour Heidari
mesh_terms: D015761:4-Aminopyridine / Q000494:pharmacology*; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D008474:Medial Forebrain Bundle / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology; D016627:Oxidopamine; D010302:Parkinson Disease, Secondary / Q000097:blood / Q000139:chemically induced* / Q000517:prevention & control*; D026902:Potassium Channel Blockers / Q000494:pharmacology*; D051381:Rats; D045442:Rotarod Performance Test; D019789:Tetraethylammonium / Q000494:pharmacology*
chemical_list: D000978:Antiparkinson Agents; D018696:Neuroprotective Agents; D026902:Potassium Channel Blockers; D008315:Malondialdehyde; D019789:Tetraethylammonium; D016627:Oxidopamine; D015761:4-Aminopyridine; D001058:Apomorphine